Agilon Health, Inc. (AGL) — SEC Filings
Agilon Health, Inc. (AGL) — 31 SEC filings. Latest: 8-K (Nov 7, 2025). Includes 9 SC 13G/A, 8 8-K, 6 10-Q.
View Agilon Health, Inc. on SEC EDGAR
Overview
Agilon Health, Inc. (AGL) is a publicly traded company tracked on ReadTheFiling. The most recent enriched filing is a 8-K filed on Nov 7, 2025: agilon health, inc. filed an 8-K on November 7, 2025, reporting a notice of delisting or failure to satisfy a continued listing rule or standard, and a transfer of listing. The filing also includes Regulation FD disclosures and financial statements and exhibits. The earliest event reported was on No
Sentiment Summary
Across 31 filings, the sentiment breakdown is: 1 bullish, 4 bearish, 25 neutral, 1 mixed. The dominant filing sentiment for Agilon Health, Inc. is neutral.
Filing Type Overview
Agilon Health, Inc. (AGL) has filed 8 8-K, 6 10-Q, 1 DEFA14A, 2 DEF 14A, 2 10-K, 9 SC 13G/A, 3 SC 13G with the SEC between Jan 2024 to Nov 2025.
Filings by Year
Recent SEC Filings (31)
Risk Profile
Risk Assessment: Of AGL's 22 recent filings, 2 were flagged as high-risk, 12 as medium-risk, and 8 as low-risk. The overall risk profile suggests moderate risk with a balanced mix of positive and cautionary disclosures.
Financial Highlights
| Metric | Value |
|---|---|
| Revenue | $4.363B |
| Net Income | -$202.5M |
| Cash Position | $171.7M |
| Total Assets | $1.596B |
| Total Debt | $34.97M |
Key Executives
- Office of the Chairman
- Dr. Paul M. R. Thomas
- Ms. Sarah M. Davis
- Mr. David L. Snow
- Ms. Jennifer L. Wagner
- Abigail P. Johnson
Industry Context
agilon health operates within the rapidly evolving healthcare industry, specifically focusing on value-based care models for Medicare Advantage beneficiaries. The competitive landscape includes other risk-bearing entities, traditional health insurers, and provider groups transitioning to value-based arrangements. Key industry trends involve increasing regulatory scrutiny, a shift towards patient-centric care, and the growing adoption of technology to manage population health and reduce costs.
Top Tags
healthcare (7) · 10-Q (5) · institutional-ownership (5) · amendment (4) · corporate-governance (3) · financials (3) · governance (3) · agilon health (3) · Healthcare (2) · Medicare Advantage (2)
Key Numbers
| Metric | Value | Context |
|---|---|---|
| Net loss for Q3 2025 | $110.2M | Improved from $117.6M net loss in Q3 2024 |
| Net loss for nine months ended Sept 30, 2025 | $202.5M | Widened from $154.3M net loss in the same period of 2024 |
| Total revenues for Q3 2025 | $1.435B | Decreased from $1.451B in Q3 2024 |
| Total revenues for nine months ended Sept 30, 2025 | $4.363B | Decreased from $4.538B in the same period of 2024 |
| Medical services expense for nine months ended Sept 30, 2025 | $4.337B | Increased from $4.324B in the same period of 2024 |
| Gain from discontinued operations for nine months ended Sept 30, 2025 | $14.0M | Compared to an $8.8M loss in the prior year |
| Cash and cash equivalents as of Sept 30, 2025 | $171.7M | Decreased from $188.2M at Dec 31, 2024 |
| Medicare Advantage members served | 502,800 | As of September 30, 2025 |
| Accumulated deficit as of Sept 30, 2025 | $1.789B | Increased from $1.587B at Dec 31, 2024 |
| Total Revenue | $1.85B | Increased 30.3% for Q2 2025 compared to Q2 2024 |
| Net Loss | $45.6M | Improved from $58.9M in Q2 2024 to $45.6M in Q2 2025 |
| Revenue Growth | 30.3% | Year-over-year increase in total revenue for Q2 2025 |
| Reporting Period | Q1 2025 | First quarter of 2025 financial performance |
| As of Date | 2025-03-31 | End of the reporting period |
| Prior Period End | 2024-12-31 | Comparison point for financial statements |
Forward-Looking Statements
- {"claim":"Agilon health's stock price may experience short-term downward pressure.","entity":"agilon health, inc.","targetDate":"Q1 2024","confidence":"medium"}
- {"claim":"Other institutional investors might re-evaluate their positions in agilon health.","entity":"agilon health, inc.","targetDate":"Q2 2024","confidence":"medium"}
- {"claim":"Capital World Investors will likely maintain a significant stake in agilon health, signaling continued institutional confidence.","entity":"Capital World Investors","targetDate":"Next 12 months","confidence":"high"}
- {"claim":"FMR LLC will likely maintain its significant stake in agilon health, inc. for the foreseeable future.","entity":"FMR LLC","targetDate":"2025-02-09","confidence":"high"}
- {"claim":"agilon health, inc. stock price may experience downward pressure due to the perceived lack of institutional confidence.","entity":"agilon health, inc.","targetDate":"Q1 2024","confidence":"medium"}
Related Companies
Frequently Asked Questions
What are the latest SEC filings for Agilon Health, Inc. (AGL)?
Agilon Health, Inc. has 31 recent SEC filings from Jan 2024 to Nov 2025, including 9 SC 13G/A, 8 8-K, 6 10-Q. Each filing includes an AI-generated plain-English summary.
What is the overall sentiment of AGL filings?
Across 31 filings, the sentiment breakdown is: 1 bullish, 4 bearish, 25 neutral, 1 mixed. The dominant sentiment is neutral.
Where can I find Agilon Health, Inc. SEC filings explained simply?
ReadTheFiling provides AI-powered plain-English summaries of all Agilon Health, Inc. (AGL) SEC filings, including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, and insider trades.
What are the key financial highlights for Agilon Health, Inc.?
Key financial highlights from Agilon Health, Inc.'s most recent 10-Q include metrics such as revenue, net income, EPS, and debt ratios. Visit the filing detail page for the full breakdown.
What is the investment thesis for AGL?
The investment thesis for AGL includes bull, base, and bear case scenarios derived from AI analysis of recent SEC filings.
Who are the key executives at Agilon Health, Inc.?
Key executives identified across Agilon Health, Inc.'s filings include Office of the Chairman, Dr. Paul M. R. Thomas, Ms. Sarah M. Davis, Mr. David L. Snow, Ms. Jennifer L. Wagner and 1 others.
What are the main risk factors for Agilon Health, Inc. stock?
Of AGL's 22 assessed filings, 2 were flagged high-risk, 12 medium-risk, and 8 low-risk.
What are recent predictions and forward guidance from Agilon Health, Inc.?
Recent forward-looking statements from Agilon Health, Inc. include guidance on {"claim":"Agilon health's stock price may experience short-term downward pressure.","entity":"agilon health, inc.","targ and 4 other predictions.